Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
|Videos|December 10, 2016
What Is The Role of the Clinical Pharmacist in the Appeals Process for Oncology Medication Reimbursement?
A Memorial Sloan-Kettering pharmacist discusses the often complicated reimbursement process for oncology medications and appeals.
Advertisement
In this clip, Jennifer Thackray, PharmD, of Memorial Sloan-Kettering discusses the often-complicated reimbursement process for oncology medications.
Advertisement
Related to this article
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
4
Community Pharmacists Guide Patients New to Glucose Monitoring
5